Xinxing jihua International Trading CO.,LTD.
Methoxy PEG Propionaldehyde



1 / 1

Methoxy PEG Propionaldehyde

≥ 95%
1g, 10g, 100g等(特殊包装需收取分装费用)
5000 Da-40000 Da,等
如需其他分子量,请联系 或 010-62983737




  键凯科技提供M-ALD分子量的5000 Da,10000 Da,20000 Da,30000 Da,40000 Da 的产品1克和10克包装。








  1. Zaghmi, A., et al., Determination of the degree of PEGylation of protein bioconjugates using data from proton nuclear magnetic resonance spectroscopy, Data in Brief, V. 25, 2019, 104037.
  2. Zaghmi, A., et al., Mechanisms of activity loss for a multi-PEGylated protein by experiment and simulation, Materials Today Chemistry, 2019, 12:121-31.
  3. Hernandez-Vargas, G., et al., Thermo-separating polymer-based aqueous two-phase systems for the recovery of PEGylated lysozyme species, Journal of Chromatography B., 2019, 1105:120-8.
  4. Cheng, Y., et al., Doxorubicin Loaded Tumor-Triggered Targeting Ammonium Bicarbonate Liposomes for Tumor-Specific Drug Delivery, Colloids and Surfaces B: Biointerfaces, 2019.
  5. Gertler, A., et al., Pegylated Human Leptin D23L Mutant–Preparation and Biological Activity In Vitro and in Vivo in Male ob/ob Mice, Endocrinology, 2019.
  6. Liu, S., et al., Acetazolamide‐Loaded pH‐Responsive Nanoparticles Alleviating Tumor Acidosis to Enhance Chemotherapy Effects, Macromolecular bioscience, 2019, 9(2).
  7. Abbasi, S., et al., Polyacrylamide–b-copolypeptide hybrid copolymer as pH-responsive carrier for delivery of paclitaxel: Effects of copolymer composition on nanomicelles properties, loading efficiency and hemocompatibility, Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2018, v. 537, p. 217-226.
  8. Behi, J., et al., Optimization of PEGylation reaction time and molar ratio of rhG-CSF toward increasing bioactive potency of monoPEGylated protein, International Journal of Biological Macromolecules, 2018, V. 109, P. 888-895.
  9. Mejia‐Manzano, L.A., et al., Optimized purification of mono‐PEGylated lysozyme by Heparin Affinity Chromatography using Response Surface Methodology, Journal of Chemical Technology and Biotechnology, 2017.
  10. Zhao, Y.Z., et al., PEGylation with the thiosuccinimido butylamine linker significantly increases the stability of haloalkane dehalogenase DhaA, Journal of Biotechnology, 2017.
  11. Mejia‐Manzano, L.A., et al., Recovery of PEGylated and native lysozyme using an in situ aqueous two‐phase system directly from the PEGylation reaction, Journal of Chemical Technology and Biotechnology, 2017.
  12. Zhang, L., et al., Suppression for lung metastasis by depletion of collagen I and lysyl oxidase via losartan assisted with paclitaxel-loaded pH-sensitive liposomes in breast cancer, Drug Delivery, 2016.
  13. Mayolo‐Deloisa, K., et al.,  PEGylated protein separation using different hydrophobic interaction supports: Conventional and monolithic supports. Biotechnology progress, 2016.
  14. Zhang, Y., et al., Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Scientific Reports, 2016, 6:21225.
  15. Mata-Gomez, M.A., et al., Modelling of electrokinetic phenomena for capture of PEGylated ribonuclease A in a microdevice with insulating structures, Biomicrofluidics, 2016, 10(3): 033106.
  16. Abbasi, S., et al., Design and cell cytotoxicity assessment of palmitoylated polyethylene glycol-grafted chitosan as nanomicelle carrier for paclitaxel. J. Appl. Polym. Sci., 2015, 133, 43233.
  17. Mayolo-Deloisa, K., et al., Aldehyde PEGylation of laccase from Trametes versicolor in route to increase its stability: effect on enzymatic activity, Journal of Molecular Recognition, 2015, 28(3): 173-179.
  18. Wu, L., et al., N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone, Molecular Pharmaceutics, 2015.
  19. Zhang, L., et al., High Tumor Penetration of Paclitaxel Loaded pH Sensitive Cleavable Liposomes by Depletion of Tumor Collagen I in Breast Cancer,  ACS Applied Materials & Interfaces, 2015.
  20. Mata-Gómez, M. A., et al., Dielectrophoretic behavior of PEGylated RNase A inside a microchannel with diamond-shaped insulating posts. Electrophoresis, 2015.
  21. Parikh, H., et al., Improving Properties of Recombinant SsoPox by Site-Specific Pegylation, Protein and Peptide Letters, 2015, 22:12.
  22. Tiwari, D., et al., Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities, Protein and Peptide Letters, 2015, 22:10, pp. 877-884(8).
  23. Schulz, J. D.,  Site-Specific Polymer Conjugation Stabilizes Therapeutic Enzymes in the Gastrointestinal Tract. Adv. Mater., 2015.
  24. Wu, L., Phenyl Amide Linker Improves the Pharmacokinetics and Pharmacodynamics of N-Terminally Mono-PEGylated Human Growth Hormone, Mol. Pharmaceutics, 2014, 11(9), p: 3080–3089.
  25. Xue, X., et al., Heat treatment increases the bioactivity of C-terminally PEGylated staphylokinase. Process Biochemistry, 2014. 49(7): p. 1092-1096.
  26. Pink, A., et al., Purification, characterization and plasma half-life of PEGylated soluble recombinant non-HA-binding CD44, BioDrugs, 2014, 28(4) p:393-402.
  27. Yu, W., et al., PEGylated recombinant human interferon-ω as a long-acting antiviral agent: Structure, antiviral activity and pharmacokinetics. Antiviral Research, 2014, 108: p. 142-147.
  28. Li, R., et al., Preparation and Characterization of Biological Non-toxic Hybrid Nanoparticles Based on Lactide and Poly(ethylene glycol) Loading Docetaxel for Anticancer Drug Delivery, Chinese Journal of Chemical Engineering, 2014, 22:11–12, P. 1357-1362.
  29. Martinez, A.H., et al., Chemical grafting of Sepharose 6B and its use in the purification of PEGylated RNase A, Separation and Purification Technology, 2014, 136, P. 190-198.
  30. Mu Q, et al., Molecular Insight into the Steric Shielding Effect of PEG on the Conjugated Staphylokinase: Biochemical Characterization and Molecular Dynamics Simulation, PLoS ONE, 2013, 8(7): e68559.
  31. Wu, L., et al., N-terminal mono-PEGylation of growth hormone antagonist: Correlation of PEG size and pharmacodynamic behavior, International journal of pharmaceutics, 2013, 453.2 : 533-540.
  32. Tian, H., et al., PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation, Journal of Pharmacy and Pharmacology, 2013, 65.1 : 53-63.
  33. Galindo‐López, M., et al., Practical non‐chromatography strategies for the potential separation of PEGylated RNase A conjugates, Journal of Chemical Technology and Biotechnology, 2013, 88.1 : 49-54.
  34. Gonzalez‐Valdez, J., et al., Effects of chemical modifications in the partition behavior of proteins in aqueous two‐phase systems: A case study with RNase A., Biotechnology progress, 2013, 29.2 : 378-385.
  35. Niv-Spector, L., Preparation and characterization of mouse IL-22 and its four single-amino-acid muteins that act as IL-22 receptor-1 antagonists, Protein Engineering, Design & Selection, 2012, 25(8). p:397-404.
  36. Mayolo-Deloisa, C., et al., Hydrophobic interaction chromatography for purification of monoPEGylated RNase A, J. Chromatogr. A, 2012, 1242 p: 11–16.
  37. Niv-Spector, L., et al., Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist, Protein Expression and Purification, 2012, 81:2, p. 186-192.
  38. Gonzalez-Valdez , J., et al., Quantification of RNase A and Its PEGylated Conjugates on Polymer-Salt Rich Environments Using UV Spectrophotometry, Analytical Letters, 2011, 44:5.
  39. Shpilman, M., et al., Development and Characterization of High Affinity Leptins and Leptin Antagonists, The Journal of Biological Chemistry, 2011, 286(6), p: 4429 –4442.
  40. Top, A., et al., Conformational and Aggregation Properties of a PEGylated Alanine-Rich Polypeptide, Biomacromolecules, 2011, 12(6), pp 2184–2192.
  41. Wang, J., et al., Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase, Analytical Biochemistry, 2011, 412: 1, P. 114-116.
  42. Gonzalez-Valdez, J., et al., Potential application of aqueous two-phase systems for the fractionation of RNase A and α-Lactalbumin from their PEGylated conjugates, J. Chem. Technol. Biotechnol., 2011, 86: 26–33.
  43. Wang, Y-J., et al., PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin, Journal of Controlled Release, 2010, 145:3, p. 306-313.
  44. Elinav, E., et al., Pegylated Leptin Antagonist Is a Potent Orexigenic Agent: Preparation and Mechanism of Activity, Endocrinology, 2009, 150(7), 3083–3091.
  46. Kateja, N., et al., Development of an integrated continuous PEGylation and purification Process for granulocyte colony stimulating factor, Journal of Biotechnology, 2020, 322, p. 79-89.
  47. Hebbi, V., et al., Process analytical technology application for protein PEGylation using near infrared spectroscopy: G-CSF as a case study, Journal of Biotechnology, 2021, 325, P. 303-311.
  48. Luo, S., et al., A new site-specific monoPEGylated β-lactoglobulin at the N-terminal: Effect of different molecular weights of mPEG on its conformation and antigenicity, Food Chemistry, 2021, 343, 128402.











Copyright © 2001-2021  北京键凯科技股份有限公司  京ICP备05043698号-1